Telehealth Journal
A searchable editorial library for weight-loss GLP-1, recovery, longevity, growth-hormone, cognitive, and sexual-health telehealth subjects. Every article includes state-aware care notes, provider-review context, safety language, FAQs, sources, and a clear CTA.
All journal articles
Semaglutide weight loss timeline: month-by-month results
A realistic month-by-month semaglutide curve built from STEP 1 and STEP 5 trial data.
Semaglutide side effects: what's normal and how long they last
Evidence-based guide to semaglutide side effects, frequency, timeline, and warning signs.
Semaglutide cost without insurance in 2026
Every cash-pay route compared with verified July 2026 pricing.
Semaglutide dosing schedule: the complete titration guide
The 0.25–2.4 mg ladder, why titration is slow, and missed-dose rules.
Compounded vs brand semaglutide (Wegovy)
FDA status, cost, and formulation differences with verified pricing.
Semaglutide and muscle loss: how to prevent it
What the data shows about lean mass and evidence-based protection.
Semaglutide beyond weight loss: prediabetes and heart health
SELECT cardiovascular data and metabolic effects explained.
Semaglutide plateau: why it happens and what to do
Why weight loss stalls and evidence-based ways to break through.
Oral vs injectable semaglutide in 2026
Effectiveness, convenience, and cost compared.
How to get semaglutide prescribed online in 2026
Eligibility, the telehealth process, and red flags to avoid.
Tirzepatide weight loss results by dose: 5, 10, 15 mg
Real SURMOUNT-1 dose-response data and how it compares to semaglutide.
Tirzepatide side effects and titration
Frequency from SURMOUNT trials, the 2.5–15 mg ladder, and management.
Tirzepatide cost without insurance in 2026
Compounded, LillyDirect vials, and brand routes with verified pricing.
Tirzepatide vs semaglutide head-to-head: SURMOUNT-5
The direct comparison trial explained and who each drug suits.
Tirzepatide for sleep apnea: the SURMOUNT-OSA breakthrough
The first drug FDA-approved for obstructive sleep apnea.
Tirzepatide dosing guide: 2.5 mg to 15 mg
The complete titration schedule and what each dose does.
Compounded vs brand tirzepatide (Zepbound)
Three cash-pay tiers including LillyDirect vials compared.
Tirzepatide plateau and maintenance
SURMOUNT-4 data on regain and how to sustain results.
Tirzepatide for type 2 diabetes (Mounjaro)
SURPASS HbA1c results, weight benefits, and coverage.
How to get tirzepatide prescribed online in 2026
Eligibility, LillyDirect vs compounded, and red flags.
Most affordable compounded semaglutide online: 2026 telehealth pricing guide
A buyer-focused guide to published cash pricing, dose escalation, provider review, and transparent GLP-1 telehealth comparison.
Most affordable compounded tirzepatide online: 2026 telehealth pricing guide
A comparison framework for flat-rate tirzepatide pricing, monthly versus multi-month plans, and state availability.
Semaglutide vs tirzepatide telehealth programs: how to compare real value
A practical comparison of clinical fit, affordability, prescribing workflow, and pharmacy fulfillment in telehealth.
How to choose a GLP-1 telehealth provider by state in 2026
A state-access guide to licensure, synchronous visit rules, pharmacy routing, and pricing caveats.
Compounded GLP-1 dosing safety: units, milligrams, and avoiding avoidable mistakes
A plain-language safety reference about concentration, units, milligrams, syringe instructions, and patient education.
Ozempic, Wegovy, Zepbound, and compounded GLP-1 programs: what patients need to compare
A compliance-first explanation of brand-name drug pathways versus compounded-medication pathways.
GLP-1 maintenance after weight loss: telehealth questions to ask before you subscribe
A patient-friendly framework for maintenance pricing, follow-up cadence, tapering discussions, and support.
Affordable GLP-1 telehealth near me: why “near me” usually means licensed in your state
State-access guide explaining why clinician licensure and pharmacy shipping availability matter more than physical proximity.
BPC-157 telehealth reference: recovery claims, pharmacy questions, and safety checks
A balanced reference on what patients ask, what needs verification, and how to avoid unsupported claims.
TB-500 peptide reference: recovery-oriented telehealth questions for 2026
A recovery-focused guide to regulatory status, physician oversight, and pharmacy sourcing questions.
BPC-157 vs TB-500: how recovery peptide pathways differ
A plain-language comparison with clear distinctions and provider checklist language.
KPV peptide reference: inflammation, skin, gut-health questions, and telehealth safeguards
An editorial reference for cautious KPV coverage with clinical-claim substantiation requirements.
Recovery peptide telehealth checklist: BPC-157, TB-500, KPV, and pharmacy verification
A state-aware checklist for recovery-oriented peptide questions and care routing.
NAD+ telehealth reference: injections, nasal protocols, and longevity-provider questions
A longevity article about NAD+ pathways, visit quality, pharmacy transparency, and realistic expectations.
Epithalon / epitalon peptide guide: longevity claims and responsible telehealth coverage
A source-conscious article for epithalon questions, focused on evidence boundaries and patient questions.
MOTS-c peptide reference: mitochondrial-health questions and telehealth safeguards
A mitochondrial-health reference focused on cautious plain-language answers and provider verification.
SS-31 and mitochondrial peptides: what longevity clinics need to explain clearly
A longevity-category article on mitochondria-focused peptides and medical-supervision questions.
Longevity peptide telehealth checklist: NAD+, epithalon, MOTS-c, and source transparency
A conversion-supporting checklist for readers evaluating longevity peptide information online.
Sermorelin telehealth guide: growth-hormone secretagogue questions for 2026
A 2026 reference for sermorelin programs, labs, patient selection, and state-specific prescribing.
CJC-1295 / ipamorelin telehealth reference: labs, protocols, and pharmacy checks
A deep reference on combination growth-hormone secretagogue questions and safety verification.
Tesamorelin guide: FDA-approved use, body-composition questions, and telehealth fit
A factual reference distinguishing FDA-approved tesamorelin use from broader wellness claims.
Ibutamoren MK-677 reference: why telehealth providers must separate supplement hype from medical review
A responsible article for MK-677 readers, focusing on labs, risk review, and quality sourcing.
Growth-hormone peptide labs: IGF-1, metabolic markers, and follow-up cadence
A practical lab-monitoring guide for growth-hormone secretagogue telehealth programs.
Sermorelin vs CJC-1295/ipamorelin: telehealth comparison for adults
A plain-language comparison between two common GH-secretagogue care categories.
Semax peptide reference: cognitive-support questions and telehealth safeguards
A careful cognitive-peptide reference about claims, mechanisms, evidence boundaries, and provider questions.
Selank peptide reference: stress-support claims and responsible telehealth information
A cognitive category reference designed to answer high-intent Selank questions without unsupported promises.
Dihexa peptide guide: cognitive-enhancement claims and what to verify before care
A safety-first guide for Dihexa questions with regulatory and pharmacy-verification framing.
P21 peptide reference: cognitive peptide research and telehealth claim boundaries
A plain-language P21 reference for readers trying to separate research interest from clinical claims.
Cognitive peptide telehealth checklist: Semax, Selank, Dihexa, and quality controls
A comparison/checklist article for cognitive-support peptide questions and source transparency.
PT-141 telehealth guide: desire, dosing questions, and prescription safeguards
A sexual-health reference distinguishing FDA-approved bremelanotide context from compounded/telehealth claims.
Oxytocin telehealth reference: intimacy claims, nasal/injection questions, and safety review
A cautious reference on oxytocin information and provider review for sexual-health telehealth.
Kisspeptin peptide guide: reproductive hormone signaling and telehealth questions
A clear guide for kisspeptin readers, focused on hormonal context, labs, and state-aware prescribing.
PT-141 vs ED medications: what telehealth patients need to compare
A high-intent comparison between desire-focused and erection-focused medication categories.
Sexual-health peptide telehealth checklist: PT-141, oxytocin, kisspeptin, and labs
A patient-facing checklist for evaluating sexual-health peptide programs and follow-up support.
Women’s and men’s sexual-health telehealth: how peptide care pathways needs to be explained
A patient-facing reference that separates indications, assessment, contraindications, and follow-up by care pathway.
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
| Evidence point | Published data | What it means for a telehealth patient |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo. | Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility. |
| Tirzepatide, SURMOUNT-1 | Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo. | Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing. |
| Compounded GLP-1 status | FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | Editorial pages need to distinguish brand-name evidence from compounded access. |
| State access | Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping. | Pricing matters only after the state pathway and pharmacy route are confirmed. |
Trial outcome chart
Sources
- STEP 1 semaglutide trial
- SURMOUNT-1 tirzepatide trial
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- CCHP state telehealth policy finder
Compare NexLife GLP-1 pricing
Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.